GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spero Therapeutics Inc (NAS:SPRO) » Definitions » EPS without NRI

Spero Therapeutics (Spero Therapeutics) EPS without NRI

: $0.51 (TTM As of Dec. 2023)
View and export this data going back to 2017. Start your Free Trial

Spero Therapeutics's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $0.97. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $0.51.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Spero Therapeutics's EPS without NRI or its related term are showing as below:

During the past 9 years, Spero Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 42.40% per year. The lowest was -18.50% per year. And the median was 5.20% per year.

SPRO's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 4.5
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Spero Therapeutics's EPS (Diluted) for the three months ended in Dec. 2023 was $0.97. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.43.

Spero Therapeutics's EPS (Basic) for the three months ended in Dec. 2023 was $0.97. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.43.


Spero Therapeutics EPS without NRI Historical Data

The historical data trend for Spero Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spero Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.36 -3.52 -2.92 -0.95 0.52

Spero Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 -0.25 -0.23 0.02 0.97

Competitive Comparison

For the Biotechnology subindustry, Spero Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spero Therapeutics PE Ratio without NRI Distribution

For the Biotechnology industry and Healthcare sector, Spero Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Spero Therapeutics's PE Ratio without NRI falls into.



Spero Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spero Therapeutics  (NAS:SPRO) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Spero Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Spero Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Spero Therapeutics (Spero Therapeutics) Business Description

Traded in Other Exchanges
Address
675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Executives
Kamal Hamed officer: Chief Medical Officer 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Sath Shukla officer: Chief Financial Officer C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BUILDING #34, BOSTON MA 02129
Timothy Keutzer officer: Chief Development Officer C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Ankit Mahadevia director, officer: See Remarks C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVE., 14TH FLOOR, CAMBRIDGE MA 02139
Tamara L Joseph officer: Chief Legal Officer 32 GARRISON STREET, APT 50-103, BOSTON MA 02116
Aquilo Capital Management, Llc 10 percent owner ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO CA 94129
Kathleen Tregoning director C/O CEREVEL THERAPEUTICS HOLDINGS, INC., 131 DARTMOUTH STREET SUITE 502, BOSTON MA 02116
Cristina Larkin officer: Chief Operating Officer C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Aquilo Capital, L.p. 10 percent owner ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, THE PRESIDIO, SAN FRANCISCO CA 94129
Scott Thomas Jackson director 303B COLLEGE ROAD EAST, PRINCETON NJ 08540
Stephen J. Dipalma officer: Interim CFO C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Cynthia Smith director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Pottage John C Jr director ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Joel Sendek officer: Chief Financial Officer C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139